

For Release August 27, 2019

Contact: Casey LoFrese, ARG Marketing Manager +1 434-485-5886 clofrese@atlanticresearchgroup.com

Atlantic Research Group Opens New European Offices

Offices in Warsaw and Amsterdam strengthen global operations, leverage existing London location, set stage for growth

CHARLOTTESVILLE, Va., WARSAW, Poland, and AMSTERDAM, August 27, 2019—Atlantic Research Group (ARG), a full-service global contract research organization (CRO), has opened new European offices in Amsterdam and Warsaw. The corporate offices, combined with an existing London location, strengthen ARG's global operations and set the stage for continued growth.

ARG now offers comprehensive clinical development within the United Kingdom, Western Europe, and Central and Eastern Europe, company executives say. An industry leader in clinical trial management in oncology, immunology, rare disease, and neurodegenerative disease, ARG was founded in 2004.

ARG has managed clinical studies in The Netherlands and Poland since 2006. By opening offices in Amsterdam and Warsaw, ARG will significantly strengthen its reach across Europe and enhance its capability to better serve small to mid-sized biotech companies.

"The new offices are the natural next steps in our controlled growth. We are excited by the cities' well-established healthcare systems, central locations, and solid overall infrastructure," Paul Bishop, CEO and cofounder said. "We can better serve Sponsors with facilitated access to new patients and sites."

Ignazio Di Giovanna, Vice-President of European Operations, added: "The timing could not be better for ARG. Opening these offices means that we are prepared for any Brexit implications in the near term. And looking to the future, these excellent locations will become gateways for regulatory guidance and organizational growth. The Amsterdam office provides us proximity to the European Medicines Agency's new home and our Warsaw office will enable us to capitalize on Poland's very impressive talent pool."

ABOUT ARG:

ARG is an oncology, immunology, rare and neurodegenerative disease-focused contract research organization that provides comprehensive clinical program development services ranging from pre-launch consulting to commercialization. Founded in 2004 with the vision that every project should be highly individualized and visible, ARG has experienced consistent growth across the globe, expanding our reach to include drug and device strategic consulting, clinical trial management services, and clinical data and analytic solutions. ARG is a disrupter, using first-in-class technology platforms along with relationship-driven flexibility to optimize clinical studies because we believe everyone deserves to be well.